Modality
Degrader
MOA
PCSK9i
Target
WRN
Pathway
Fibrosis
ASMelanomaAtopic Derm
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
Oct 2017
→ Jul 2026
Phase 1Current
NCT05753419
2,717 pts·Atopic Derm
2017-10→TBD·Terminated
NCT08181552
1,092 pts·Melanoma
2025-09→2026-07·Not yet recruiting
3,809 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-07-224mo awayPh2 Data· Melanoma
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1/2
Termina…
P1/2
Not yet…
Catalysts
Ph2 Data
2026-07-22 · 4mo away
Melanoma
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05753419 | Phase 1/2 | Atopic Derm | Terminated | 2717 | UPCR |
| NCT08181552 | Phase 1/2 | Melanoma | Not yet recr... | 1092 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR |